This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ciclesonide for the Treatment of Airway Hyperresponsiveness

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: January 21, 2009
Last updated: December 1, 2016
Last verified: October 2016
The study objective is to investigate in a placebo-controlled, double-blind manner the effect of inhaled corticosteroid (ciclesonide) on airway hyperresponsiveness measured as having PD15 mannitol. Treatment medication will be administered as follows: 320 microgram ciclesonide or placebo will be inhaled once daily. The study duration consists of a treatment period of 4 weeks. The study will provide further data on safety of ciclesonide.

Condition Intervention Phase
Asthma Drug: Ciclesonide Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-blind, Randomized, Parallel Group Study.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change of hyper-responsiveness to mannitol assessed by PD15FEV1 after 4 weeks of treatment with ciclesonide vs Placebo [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • RDR mannitol (response-dose-ratio = %fall in FEV1 / provocation dose given) [ Time Frame: 4 weeks ]
  • Responsiveness to methacholine (PD20FEV1 ) and RDR methacholine after 4 weeks of treatment [ Time Frame: 4 weeks ]
  • Level of exhaled nitric oxide after 4 weeks of treatment [ Time Frame: 4 weeks ]
  • mean improvement of FEV1 and PEF, mean change of the asthma control questionnaire ACQ (Juniper) [ Time Frame: 4 weeks ]
  • Mean change of ACQ after 4 weeks of treatment [ Time Frame: 4 weeks ]
  • Mean change of AQLQ after 4 weeks of treatment [ Time Frame: 4 weeks ]
  • Mean change of symptoms, rescue medication use, nocturnal awakening according to GINA after 4 weeks of treatment [ Time Frame: 4 weeks ]
  • Exacerbation rates during the 4 weeks of treatment [ Time Frame: 4 weeks ]

Enrollment: 64
Study Start Date: September 2008
Study Completion Date: October 2011
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Ciclesonide 320µg
Drug: Ciclesonide
320µg Ciclesonide versus Placebo
Placebo Comparator: 2
Drug: Placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Referred to the pulmonology department of the university hospital Basel because of suspected asthma defined as respiratory symptoms like wheezing or cough or chest tightness.
  2. Asthma symptoms partly controlled according to GINA (October 2006) 1 week prior to randomization
  3. FEV1 ≥ 70% predicted
  4. 18 - 70 years old

Exclusion Criteria:

  1. Smoker and ex-smoker with >10 pack years
  2. COPD
  3. Upper respiratory tract infection within the past 4 weeks.
  4. ICS or oral steroids during the previous month before inclusion
  5. b-blockers within the past 4 weeks
  6. Current treatment with medication as defined in section concomitant medication (ICS other than study medication, ß-blockers)
  7. Pregnancy
  8. Known malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826969

Basel, Switzerland, 4031
Sponsors and Collaborators
Study Director: AstraZeneca AstraZeneca AstraZeneca
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00826969     History of Changes
Other Study ID Numbers: BY9010/CH-101
U1111-1137-3949 ( Registry Identifier: WHO )
Study First Received: January 21, 2009
Last Updated: December 1, 2016

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Respiratory Hypersensitivity
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Hypersensitivity, Immediate
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents processed this record on June 22, 2017